In May, CSL Behring announced upgrades to its HeliTrax™ System for patients with hemophilia A who use Helixate® FS, Antihemophilic Factor (Recombinant). With a new password-protected Web interface, patients can input their treatment data and monitor their condition online even when they do not have their handheld electronic device on hand.

CSL Behring launched the wireless electronic data management system in 2008 to help improve communication between patients and the staff at hemophilia treatment centers. Once the patient enters information into the Web site or handheld device about bleeds and dosing, the patient and treatment team can keep track of the details. Upgrades include the ability for:  patients to record other types of therapies used in their treatment; multiple patients in a family to use the same device; multiple providers to access the system using individual log-ins; and additional data collection.

“Managing hemophilia can be challenging for patients and their caregivers,” said Garrett E. Bergman, MD, CSL Behring’s Senior Director, Medical Affairs, U.S. Commercial Operations. “These enhancements will make it easier and more convenient for patients to record and monitor their infusions and easier for the hemophilia treatment team to manage the patient’s therapy.”

Source: CSL Behring news release dated May 4, 2009